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Introduction 
DNA delivery provides a mechanism to directly alter en-
dogenous gene expression and cellular behavior with 
applications in functional genomics [1], tissue engineering 
[2], medical devices [3] and gene therapy [4, 5]. Viruses 
and the profuse knowledge about the molecular media-
tors of viral infection [6] have been exploited to develop 
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Abstract 
Background — Design of efficient nonviral gene delivery systems is limited as a result of the rudimen-
tary understanding of the specific molecules and processes that facilitate DNA transfer. 
Methods — Lipoplexes formed with Lipofectamine 2000 (LF2000) and plasmid-encoding green fluorescent 
protein (GFP) were delivered to the HEK 293T cell line. After treating cells with lipoplexes, HG-U133 Af-
fymetrix microarrays were used to identify endogenous genes differentially expressed between treated 
and untreated cells (2 h exposure) or between flow-separated transfected cells (GFP+) and treated, un-
transfected cells (GFP–) at 8, 16 and 24 h after lipoplex treatment. Cell priming studies were conducted 
using pharmacologic agents to alter endogenous levels of the identified differentially expressed genes 
to determine effect on transfection levels. 
Results — Relative to untreated cells 2 h after lipoplex treatment, only downregulated genes were iden-
tified ≥ 30-fold: ALMS1, ITGB1, FCGR3A, DOCK10 and ZDDHC13. Subsequently, relative to GFP– cells, 
the GFP+ cell population showed at least a five-fold upregulation of RAP1A and PACSIN3 (8 h) or HSPA6 
and RAP1A (16 and 24 h). Pharmacologic studies altering endogenous levels for ALMS1, FCGR3A, and 
DOCK10 (involved in filopodia protrusions), ITGB1 (integrin signaling), ZDDHC13 (membrane traffick-
ing) and PACSIN3 (proteolytic shedding of membrane receptors) were able to increase or decrease 
transgene production. 
Conclusions — RAP1A, PACSIN3 and HSPA6 may help lipoplex-treated cells overcome a transcriptional 
shutdown due to treatment with lipoplexes and provide new targets for investigating molecular mech-
anisms of transfection or for enhancing transfection through cell priming or engineering of the non-
viral gene delivery system. 
Keywords: ALMS1, FCGR3A, GFP, HEK 293T, ITGB1, microarray analysis, nonviral gene delivery, tempo-
ral gene expression profile 
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very efficient viral gene delivery systems [7]. However, on-
cogenicity, immunogenicity, and the lack of repeated dosing 
capability [8–11] of viruses have spurred research towards 
enhancing the efficacy of nonviral DNA carriers. Nonviral 
carriers such as cationic lipids (i.e. lipoplexes) [12–20] and 
polymers (i.e. polyplexes) [21] do not have the problems 
associated with viruses but suffer from low transfection. 
However, an incomplete understanding of the molecules 
and mechanisms that facilitate successful nonviral transfec-
tion precludes the efficient design of more efficient nonvi-
ral systems [19, 22–24]. 
Towards a better understanding of nonviral transfection, 
transcriptome profiling has been used to identify the cellu-
lar and tissue response after treatment with nonviral gene 
carriers by comparing treated samples with untreated sam-
ples [23, 25–29]. For example, a previous study used micro-
arrays to identify the in vivo cellular response to treatment 
of lipoplexes and found type I interferon to be upregu-
lated in the spleen after treatment of polyethylene gly-
col-modified lipoplexes as a result of delayed endosomal 
escape. That study provided a molecular framework to re-
design the DNA carrier for improved safety of the lipo-
plex, informed through comparison of the gene expression 
profiles of treated tissue to untreated tissue [7]. However, 
that work was limited in that molecules facilitating trans-
fection were not identified (i.e. no comparison of gene pro-
files from treated and transfected cells to treated but un-
transfected cells was made) to provide a molecular basis 
to redesign the DNA carrier for improved transfection ef-
ficiency. Another study used microarrays to highlight the 
time- and vector-dependence of the gene expression profile 
of cells treated in vitro with lipoplexes, which showed dif-
ferent types of endogenous genes being over- and under-
expressed at 8 h (stress-inducible, immune response, anti-
viral, cellular growth and division), 24h (cellular growth and 
division, G protein-coupled receptors, heat shock proteins, 
transcription/translation effectors, proteasome, senescence 
and cytoskeletal) and 48 h (cellular growth and division, 
transcription/translation effectors, Golgi-endoplasmic retic-
ulum trafficking, heat shock proteins, DNA repair, cytoskel-
etal, and motility) [30] after DNA delivery, although, again, 
in that work, transfected cells were not studied in isolation 
and therefore the data provide information about cellular 
response to treatment with lipoplexes but not about mech-
anisms that facilitate transfection. Gene expression profiling 
has also been useful in assessing specific genes expressed 
by epithelial cells in vitro to cope with treatment-induced 
cytotoxicity and apoptosis, highlighting genes such as inter-
leukin-9 receptor (IL-9R), heat shock protein 70 (HSP70) and 
met proto-oncogene precursor (cMET) upregulated in cells 
in lipoplex transfection [26]. Together, these previous stud-
ies show the usefulness of microarray analysis to identify 
genes and pathways elicited after treatment of cells or tis-
sues with nonviral gene delivery systems and that the gene 
expression profile can vary drastically at various time points 
after treatment with lipoplexes. However, a substantial gap 
in knowledge remains about molecules and pathways used 
by cells to overcome the different barriers that occur over 
time during DNA transfer [21, 31–43]. 
To identify mechanisms that facilitate transfection (i.e. 
successful delivery of the transgene), a lipoplex-treated 
population of cells can be separated into two subpopu-
lations (transfected and untransfected) and, subsequently, 
their transcriptome can be profiled using microarray anal-
ysis. When transfected and untransfected gene expression 
profiles are compared, the identified differentially expressed 
genes provide insight into molecules and mechanisms that 
facilitate transfection [44, 45]. For example, in our previously 
published study, we showed RAP1A and HSPA6 endogenous 
genes to be overexpressed in transfected human embry-
onic epithelial kidney (HEK 293T) cells 24 h after delivery of 
the GFP transgene using lipoplexes [45] or polyplexes [44], 
compared to treated but untransfected cells. Subsequently, 
priming cells for transfection by altering RAP1A or HSPA6 
endogenous levels prior to polyplex or lipoplex treatment, 
respectively, resulted in an up to 2.5-fold increase in trans-
fection [44, 45]. Those studies demonstrated that transfec-
tion can be improved by targeting specific molecules that 
are over- or under-expressed in transfected cells compared 
to untransfected cells. Although targeting a single barrier 
or step in DNA transfer often leads to improved transfec-
tion [46], it is unlikely that consideration of a single endog-
enous gene in DNA carrier design will lead to a therapeu-
tically relevant transfection system. Instead, multi-faceted 
approaches generally lead to improved transfection [47], al-
though the genes and pathways implicated at other, earlier 
stages of transfection (e.g. internalization, endosomal es-
cape, nuclear localization, nuclear entry) [21, 31–43] remain 
unidentified and prevent the design of efficient gene deliv-
ery systems. Because lipid and polymer DNA carriers have 
shown promising in vitro and in vivo transfection [47], the 
aim of the present study is to identify genes and pathways 
implicated at these earlier stages for lipid vectors, whereas 
our other work focuses on polymer vectors [48]. 
The objective of the present study was to identify en-
dogenous genes differentially expressed at 2, 8, 16 and 
24 h after delivery of the GFP transgene to HEK 293T cells 
using a cationic lipid vector (Lipofectamine 2000; LF2000). 
Relative to untreated cells, transcriptome profiling of HEK 
293T cells at 2 h post-delivery of lipoplexes was used to 
identify those endogenous genes that may act in response 
to treatment stress such as toxicity induced by the com-
plex [22] or inherent intracellular defenses against foreign 
nucleic acids [49]. Relative to GFP– cells, transcriptome 
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profiling was used to identify those endogenous genes 
used by transfected cells (GFP+) that may aid in overcom-
ing cellular barriers known to occur during DNA transfer 
[21, 31–43] at 8, 16 and 24 h post-delivery of lipoplexes. 
Events that typically take place 8 h after delivery of com-
plexes to the cells include a high rate of endosomal escape 
[31, 33], unpacking of plasmid DNA (pDNA) from vector 
[31, 32], some nuclear localization of complexes or pDNA 
[31, 33–36], very small amounts of nuclear internalization 
of complexes or pDNA [34, 36, 37] and very little produc-
tion of transgenic protein [34, 38]. Events that typically 
take place 16 h after delivery of complexes to the cells 
include high rate of nuclear localization of complexes or 
pDNA [34, 36], continued nuclear internalization of com-
plexes or pDNA [21, 34, 36, 37] and continued produc-
tion of transgenic proteins [34,38]. Events that take place 
24 h after delivery of complexes to the cells include the 
continued nuclear internalization of pDNA [34,36,37,40], 
the highest synthesis of transgenic proteins [34, 38, 40] 
and mitosis (including distribution of transgenic proteins 
and pDNA to daughter cells) [36, 39]. Therefore, the time 
points chosen for the investigations in the present study 
were selected to capture several key cellular events that 
occur throughout the gene delivery process. We also as-
certained the potential role of several of the identified 
genes for their ability to affect transfection by use of phar-
macologic activators or inhibitors of the target endoge-
nous gene. The endogenous genes and pathways that fa-
cilitate transfection as identified in the present study can 
be used as targets for increasing transfection through cell 
priming or for improved DNA carrier design. 
Materials and methods 
Cell culture and plasmid preparation 
HEK 293T cells (ATCC, Manassas, VA, USA) were cultured in 
T-75 flasks in Dulbecco’s modified Eagle’s medium contain-
ing 4.5 g/l glucose, supplemented with 10% fetal bovine 
serum, 1mM sodium pyruvate, 100 units/ml of penicillin-
streptomycin (all Gibco, Carlsbad, CA, USA) and maintained 
at 37°C in a humidified 5% CO2 atmosphere. For seeding, 
cells were dissociated at confluence with 1mM ethylenedi-
aminetetraacetic acid (EDTA) and viable cells were counted 
using a hemocytometer and trypan blue dye exclusion as-
say. Plasmid pEGFP-LUC encodes both the enhanced green 
fluorescent protein (EGFP) and firefly luciferase protein 
(LUC) under the direction of a cytomegalovirus promoter 
(Clontech, Mountain View, CA, USA), and was used for 
transfection experiments (see below). Plasmid was purified 
from bacteria culture using Qiagen (Valencia, CA, USA) re-
agents and stored in Tris–EDTA buffer solution (10mM Tris, 
1mM EDTA, pH 7.4) at –20°C. 
Transfection and sample isolation for microarray 
Cells were seeded at a density of 44.8×103 cells/cm2 into 
multiple T-75 flasks. After adherence (approximately 18 
h after seeding), lipoplexes were formed using LF2000 in 
accordance with the manufacturer’s instructions (Invitro-
gen, Carlsbad, CA, USA). Briefly, LF2000 transfection re-
agent diluted in serum-free Opti-MEM media (Invitrogen) 
was added dropwise to DNA diluted in Opti-MEM at a lipid: 
DNA ratio of 1.5:1, mixed by gentle pipetting, and incu-
bated at room temperature for 20 min. After forming the 
lipoplexes, they were delivered to the media above the cells 
to deliver 0.15 μg/cm2 of DNA. Those transfection condi-
tions were optimal for high transfection (typically 70–90%) 
and low cytotoxicity with optimization performed as de-
scribed previously [45]. The complexes remained in con-
tact with the cells for the duration of each experiment: 
2, 8, 16 and 24h. After the incubation period of the li-
poplexes at each time point, cells were dissociated using 
0.05% Trypsin-EDTA (except only EDTA for the 2-h con-
dition) and suspended in 1X phosphate-buffered saline 
(PBS) at 2–5 million cells/ml and placed on ice. For the 2-h 
time point, because very little GFP had been produced, 
untreated samples were obtained identically, as were the 
treated samples, except no lipoplexes were delivered to 
the cells. For the 8-, 16- and 24-h time points, after disso-
ciation, the treated cells were separated into transfected 
(GFP+) and untransfected (GFP–) pure cell populations us-
ing fluorescence activated cell sorting (FACS), as described 
previously [45]. Briefly, at 8, 16 or 24 h after the addition of 
complexes, cells were dissociated, counted, and concen-
trated in 1X PBS and placed on ice, as described above. 
Flow cytometric analysis was performed using a B-D FAC-
SVantage SE three-laser, high speed cell sorter (University 
of Nebraska–Lincoln’s Center for Biotechnology Flow Cy-
tometry Core Facility) equipped with a 530/15 nm SE la-
ser. A live gate was set on the GFP+ cell population in for-
ward scatter versus side scatter plot to remove cell debris 
or clumped cells from the sort. A minimum of 2×106 cells 
for each population (GFP+, GFP–) was collected. Cells were 
collected at each time point on three different days pro-
viding the following independent samples (n=3 for each 
sample): 2 h treated, 2 h untreated, 8 h GFP+, 8 h GFP–, 16 
h GFP+, 16 h GFP–, 24h GFP+ and 24 h GFP– (for an over-
view of the experimental design, see Figure 1). RNA from 
each sample was then extracted, purified and hybridized 
to microarrays (see below).  
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RNA extraction and microarray hybridization 
RNA extraction and quality check was performed as de-
scribed previously [45]. Briefly, after obtaining each sam-
ple (24 in total: three each for 2 h treated, 2 h untreated, 8 
h GFP+, 8 h GFP–, 16 h GFP+, 16 h GFP–, 24 GFP+ and 24 
h GFP–; see also above and Figure 1), total RNA was TRIzol 
extracted and further purified using a Qiagen RNeasy col-
umn (Qiagen) to achieve a 260/280 ratio greater than 1.8 
on Nanodrop 2000 (Thermo Scientific, West Palm Beach, 
FL, USA). After quality assessment using an RNA 6000 Nano 
LabChip on an Agilent BioAnalyzer 2100 (Agilent Technolo-
gies, Santa Clara, CA, USA), purified RNA was reverse tran-
scribed to cDNA and hybridized to Affymetrix GeneChip 
Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa 
Clara, CA, USA) overnight at 45°C, in accordance with the 
manufacturer’s instructions. After streptavidin-phycoery-
thrin conjugate staining, expression data were read with the 
GeneChip Scanner 3000 7G (Affymetrix) to obtain the ex-
pression data of over 47 000 transcripts and variants anno-
tated for all known genes of the human genome. Affyme-
trix GeneChip Operating Software (GCOS, version 1.3) was 
used for washing, scanning and basic data analysis, includ-
ing calculation of absolute values and normalization of the 
data with respect to internal standards. 
Microarray and bioinformatics analyses 
Each microarray provides 11 independent measures of gene 
expression (n=11) for over 47,000 transcripts and variants 
annotated for all known genes of the human genome. 
Figure 1. Overview of the experimental design (see Materials and methods). HEK 293T cells were seeded and allowed to become 
adherent (approximately 18 h). Then, lipoplexes were formed and delivered to adherent cells and allowed to remain in contact for 2, 
8, 16 or 24 h. At the 2-h time point, treated cells were harvested and RNA was extracted and hybridized to microarrays. The treated 
profile was compared with cells that underwent the same treatments, except no lipoplexes were delivered. At the 8-, 16- or 24-h time 
points, treated cells were FACS separated into GFP positive (GFP+; transfected) and GFP negative (GFP–; untransfected) cell popu-
lations and RNA was extracted and hybridized to microarrays. The process was repeated on separate days to achieve n=3 for each 
population at each time point.  
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Microarray expression data were background adjusted and 
normalized [50] and quality tested using R/Bioconduc-
tor with the AffyCoreTools library package, with all arrays 
showing good hybridization quality, as described previ-
ously [44,45]. The gene expression data has been depos-
ited at the NCBI Gene Expression Omnibus (GEO) accession 
GSE59666. Differentially expressed genes between treated 
and untreated (2-h time point) or GFP+ and GFP– (8-, 16- 
and 24-h time points) were determined using a nonpara-
metric mean-variance smoothing method developed for 
R programming environment [51]. Microarray data for the 
24-h time point were collected previously and analyzed us-
ing linear models [45] and were downloaded from GEO ac-
cession GSE20615. Those microarrays were again analyzed 
here, using the nonparametric smoothing method, which 
resulted in a larger gene set differentially expressed be-
tween GFP+ and GFP– gene expression profiles than has 
been previously reported. Those results are included in the 
present study, along with the pathways and ontologies en-
riched to the new gene set (see below). Genes differentially 
expressed greater than two-fold and posterior probability 
greater than 0.99 were used for the bioinformatics analy-
sis. Enrichr [52], an open source and freely available gene 
list enrichment analysis tool, was used to identify enriched 
pathways for Kyoto Encyclopedia of Genes and Genomes 
(KEGG) [53], WikiPathways (WIKI) [54], BioCarta [55], pro-
tein–protein interacting proteins (PPI Hub Proteins) [56], 
The Comprehensive Resource of Mammalian Protein Com-
plexes (CORUM) [57], Reactome [58] and Gene Ontology 
Process (GO) [59]. Each list of differentially expressed genes 
was uploaded to the Enrichr [52] website and pathways or 
ontologies enriched greater than a combined score of 5 
were reported. The combined score is computed by tak-
ing the log of the p-value from the Fisher’s exact test mul-
tiplied by the Z-score of the deviation from the expected 
rank [52]. Among the differentially expressed genes, the 
most promising genes that may affect transfection were 
identified. The genes were selected based on high differ-
ential expression, putative gene role and potential to play a 
role in processes that are known to occur during DNA trans-
fer [21, 31–43], and exploratory gene association network 
(EGAN) analysis [60]. EGAN analysis was performed as pre-
viously described [44] but, briefly, the tool was used to vi-
sualize common occurrences among gene–gene interac-
tions and enriched pathways/ontologies [60] and aided in 
selecting genes to study further (see Supporting informa-
tion, Figure S1). After identifying target genes, the NextBio 
[61] Pharmaco Atlas was used to identify pharmacologic 
agents known to upregulate or downregulate the target 
gene with a score above 70. Those pharmacologic agents 
were then used for transfection studies in the presence of 
pharmacologic agents (see below). 
Transfection in the presence of pharmacologic agents 
These experiments were performed as previously described 
to alter the expression of endogenous target genes iden-
tified from microarray analysis [45]. The studies acted pri-
marily as a screening tool to confirm whether a particular 
gene plays an important role in the DNA transfer process. 
Briefly, transfection studies were performed in the pres-
ence and absence of pharmacologic activators or inhibi-
tors of the target genes (selected as described above). HEK 
293T cells were seeded in 48-well plates at 44.8×103 cells/
cm2 and, 18h later, pharmacologic agents were delivered 
to the media on the cells to achieve the final desired drug 
concentration. The pharmacologic agent was allowed to 
incubate for 1 h, and then lipoplexes were formed (as de-
scribed above) and delivered to the media above the cells 
(still containing the pharmacologic agent). The pharmaco-
logic agent and lipoplexes remained in contact with the 
cells for the next 24 h and then the cells were lysed and 
transfection levels were quantified by measuring the lucif-
erase activity (relative light units) using the Luciferase As-
say System (Promega, Madison, WI, USA) and luminometer 
(Turner Designs, Sunnyvale, CA, USA), and luciferase activ-
ity was normalized to the total protein amount determined 
with the BCA protein assay (Pierce, Rockford, IL, USA) and 
compared with transfection levels in vehicle-only control 
cells. The results were reported as the fold-change to elim-
inate variability in absolute measures of transfection, re-
spectively, for ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3 
and ZDDHC13 genes; pharmacologic activators included 
phenethicillin [62], 1,10-phenanthroline [63], ritonavir [64], 
nifenazone [62], hydralazine hydrochloride [62], β-acetyl-
γ-O-hexadecyl-l-α-phosphatidylcholine hydrate (B-AGO-
PCL) [65]; and pharmacologic inhibitors included quipazine 
[62], artemisinine [64,66], gentamicin [64], 8-methoxyp-
soralen [62], valsartan [64] and nicergoline [62] (all from 
Sigma- Aldrich, St Louis, MO, USA). The concentrations of 
the pharmacologic agents selected for the present study 
were comparable to those tested in the literature showing 
gene activity [62, 64–66] but were optimized for high trans-
fection and minimal toxicity (not shown) (see Supporting 
information, Figure S2). Statistical analysis was performed 
using Prism, version 5 (GraphPad, La Jolla, CA, USA) using 
Student’s t-test at a 95% confidence level. Data are reported 
as the mean±SEM (n=3). 
Results 
The GFP transgene was delivered to HEK 293T cells us-
ing LF2000 transfection reagent. Then, 2 h after delivery 
of the lipoplexes, the initial cell response was determined 
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using microarray analysis. Changes in the transcriptome 
were identified by comparing gene expression profiles of 
cells treated with lipoplexes with cells not treated by lipo-
plexes (Figure 1). All genes found to be differentially ex-
pressed two-fold or greater are listed in the Supporting 
information (Table S1). Among the greatest differentially 
expressed genes in treated cells compared to untreated 
cells were: ALMS1, ITGB1, FCGR3A, DOCK10 and ZDDHC13, 
which were downregulated 34.5-, 35.7-, 38.5-, 43.5- and 
50.0-fold, respectively (Table 1). Among all genes differ-
entially expressed between treated and untreated cells at 
the 2-h time point (see Supporting information, Table S1), 
only LIMS1 and ITGB1 were found to be enriched to cel-
lular pathways including cell migration, the inflammatory 
response, cell adhesion and cell junctions (Table 2). Taken 
together, treated cells were shown to undergo rapid tran-
scriptional changes in response to treatment with lipoplexes 
in a highly downregulated manner. 
Because most cells internalize lipoplexes within the first 
few hours of exposure [21,31,33,34,41–43; Sarah A. Plautz 
(S.A.P) unpublished results] but not all cells actually express 
the transgene, we next set out to identify those endoge-
nous genes that may facilitate transfection. To do so, li-
poplexes were delivered to the cells and, after 8, 16 or 24 
h, the treated cell population was sorted into transfected 
GFP+ and GFP– subpopulations (Figure 1). Using microar-
ray analysis, changes in the transcriptome were identified 
by comparing GFP+ and GFP– endogenous gene expression 
Table 1. Differentially expressed genes comparing treated with untreated gene expression profiles after 2 h of exposure to lipoplexes
Gene  Fold Δ  Name
ALMS1  –34.5  Alstrom syndrome 1
ZDHHC13  –35.7  Zinc finger, DHHC-type containing 13
ITGAL  –37.0  Integrin, alpha L [antigen CD11A (p180), lymphocyte
     function-associated antigen 1; alpha polypeptide]
AI912723  –38.5  NA
CCDC30  –38.5  Coiled-coil domain containing 30
FCGR3A  –38.5  Fc fragment of IgG, low affinity IIIa, receptor (CD16a)
SLC24A2  –41.7  Solute carrier family 24 (sodium/potassium/calcium exchanger),
     member 2
CLLU1  –41.7  Chronic lymphocytic leukemia up-regulated 1
ANXA6  –41.7  Annexin A6
ITGB1  –43.5  Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen
     CD29 includes MDF2, MSK12)
PER1  –43.5  Period homolog 1 (Drosophila)
TPTE  –45.5  Transmembrane phosphatase with tensin homology
RRM1  –50.0  Ribonucleotide reductase M1
DOCK10  –50.0  Dedicator of cytokinesis 10
BC040304  –55.6  NA
SLC3A1  –62.5  Solute carrier family 3 (cystine, dibasic and neutral amino acid transporters,
     activator of cystine, dibasic and neutral amino acid transport), member 1
BCL2L10  –83.3  BCL2-like 10 (apoptosis facilitator)
Fold change indicates differential expression of HEK 293T cells transfected with pEGFPLuc/LF2000 microarrays (n=3) compared to untreated 
microarrays (n=3) with a posterior probability greater than 0.99 at the 2-h time point. Negative numbers indicate downregulation.
NA: not available.
Table 2. Enriched pathways for genes differentially expressed between treated and untreated gene expression profiles after 2 h of exposure to 
lipoplexes
Source  Term  Score  Genes
KEGG  Leukocyte transendothelial migration (HSA04670)  5.21  LIMS1, ITGB1
BioCarta  Local acute inflammatory response (LAIR)  11.84  LIMS1, ITGB1
GO  Leukocyte adhesion (GO: 0007159)  7.14  LIMS1, ITGB1
GO  Integrin complex (GO: 0008305)  8.26  LIMS1, ITGB1
GO  Focal adhesion (GO: 0005925)  7.08  LIMS1, ITGB1
GO  Cell-substrate junction (GO: 0030055)  6.69  LIMS1, ITGB1
GO  Adherens junction (GO: 0005912)  5.60  LIMS1, ITGB1
Genes found in Table 1 and the Supporting information (Table S1) were found to be over-represented to specific terms. The first column indicates 
the source of pathway database; the second column lists the enriched term; the third column lists the enrichment score; and the last column 
indicates which of the differentially expressed genes belong to the enriched term. Downregulated genes are shown in italic, and genes greater 
than five-fold differentially expressed are shown in bold. For a description of the source or score, see Materials and methods.
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profiles. All genes found to be differentially expressed two-
fold or greater are listed in the Supporting information (Ta-
ble S1). At the 8-h time point, the greatest differentially 
expressed genes were RAP1A and PACSIN3, both upregu-
lated 38.62- or 6.64-fold, respectively (Table 3). At the 16-h 
time point, the greatest differentially expressed genes were 
RAP1A and HSPA6, upregulated 17.30- or 7.42-fold, respec-
tively (Table 3). At the 24-h time point, the greatest differen-
tially expressed genes were once again RAP1A and HSPA6, 
upregulated 10.28- or 11.35-fold, respectively (Table 3). 
We were next interested in understanding how the gene 
expression profile changes over time, in terms of the num-
ber of genes expressed, as well as which genes were found 
to be differentially expressed over multiple time points. The 
number of genes differentially expressed (between GFP+ 
and GFP–) increased from 8 h to 16 h from seven genes to 
27 genes, respectively (Figure 2). ARMC8, ATF3 and RAP1A 
genes were commonly expressed between the two time 
points (Figure 2). The number of genes differentially ex-
pressed decreased from 16 h to 24 h from 27 genes to 
two genes (Figure 2), respectively, with HSPA6 and RAP1A 
genes commonly being expressed between the two time 
points (Figure 2). RAP1A showed sustained upregulation in 
the transfected cell population compared to untransfected 
cell population at the 8-, 16- and 24-h time points (Figure 
2; see also Supporting information, Table S1). The largest 
number of genes differentially expressed occurred 16 h af-
ter exposure to lipoplexes in the transfected cell population. 
To determine the role of all differentially expressed genes 
in transfected cells at each time point (8, 16 and 24 h; see 
Supporting information, Table S1), we performed a pathway 
and ontology enrichment analysis (Table 4; see Materials 
and methods). Pathways enriched from genes differentially 
expressed at the 8-h time point were the mesenchymal–ep-
ithelial transition (MET) and integrin pathways, protein com-
plexes (CLTH, HSPA1A and SMARCA4) and GO processes in-
volved in metabolism, proteolysis and catabolism (Table 4). 
Pathways enriched at the 16-h time point were spindle and 
cell cycle pathways, as well as protein complexes involved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
in cell adhesion (RIAM-Rap1-GTP complex), proliferation 
(CDC2-PCNA-CCNB1-GADD45A complex) and stimuli re-
sponse (MAPK9) (Table 4). Pathways enriched at the 24-h 
time point were focal adhesion, migration, MET, integrin 
and stimuli response (mitogen-activated protein kinase, IL-
3, type I interferon, unfolded protein response) pathways, 
along with protein complexes involved in paracrine signal-
ing (HGFR), GTPase activity, transport (GABARAPL2) and 
cell adhesion (RIAM-Rap1-GTP complex) (Table 4). Taken 
together, the pathways and ontologies enriched at each 
time point may play a role in transfection, and those genes 
differentially expressed greater than five-fold at each time 
point may play a significant role in those processes because 
Table 3. Temporal cell response after treatment with lipoplexes comparing GFP+ to GFP– gene expression profiles
Time  Gene  Fold  Posterior probability  Accession number  Name
8 h  RAP1A  38.62  1.00  AB051846  RAP1A, member of RAS oncogene family
 PACSIN3  6.64  1.00  AK000847  Protein kinase C and casein kinase substrate in neurons 3
16 h  RAP1A  17.30  1.00  AB051846  RAP1A, member of RAS oncogene family
 HSPA6  7.42  1.00  NM_002155  Heat shock 70-kDa protein 6 (HSP70B’)
24 h  RAP1A  10.28  1.00  AB051846  RAP1A, member of RAS oncogene family
 HSPA6  11.35  1.00  NM_002155  Heat shock 70-kDa protein 6 (HSP70B’)
Comparison of GFP+ to GFP– gene expression levels. Differential expression greater than or less than 1 represents upregulation or downregulation, 
respectively. Data represent genes differentially expressed comparing transfected microarrays (n=3) with treated, untransfected microarrays (n=3) 
with a posterior probability greater than 0.99 and differential expression greater than five-fold. The Supporting information (Table S1) lists all genes 
differentially expressed greater than two-fold.
Figure 2. The overlap of genes differentially expressed between 
the GFP+ and GFP– gene expression profiles is shown for each 
time point. Data represent genes greater than two-fold differen-
tially expressed comparing transfected microarrays (GFP+; n=3) 
with treated, untransfected microarrays (GFP–; n=3) with a pos-
terior probability >0.99. The level of differential expression for 
each gene is provided in the Supporting information (Table S1). 
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they are highly upregulated: 8 h (PACSIN3 and RAP1A), 16 h 
(RAP1A and HSPA6) and 24 h (RAP1A and HSPA6) (Table 4). 
As reported in the present study, microarray analysis re-
vealed genes highly differentially expressed in treated cells 
compared to untreated cells at the 2-h time point and in 
GFP+ cells compared to GFP– cells at the 8-, 16- and 24-h 
time points (Tables 1 and 3). To discriminate whether any 
of the genes identified in the present study have a poten-
tial role in transfection as opposed to genes expressed as 
a treatment effect, pharmacologic studies were conducted. 
Those genes highly differentially expressed at the 2-, 8-, 
16- or 24-h time points (Tables 1 and 3) were narrowed to 
a smaller subset to further test based on literature review 
of each gene’s putative function, potential role in the DNA 
transfer process and exploratory gene association network 
analysis [60] (see Supporting information, Figure S1; Ma-
terials and methods). Highly differentially expressed genes 
RAP1A and HSPA6 (Table 3) were not studied using phar-
macologic agents because we have previously shown that 
perturbing those genes prior to lipoplex delivery can en-
hance transfection by up to 2.5-fold [45]. The list of genes 
was narrowed to ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3 
and ZDDHC13. Pharmacologic agents known to activate or 
inhibit each gene were found using NextBio [61] and from 
previous studies in the literature [62–66], and were used as 
a screening tool to confirm whether a particular gene may 
play an important role in the DNA transfer process. The ef-
fect of the pharmacologic agent on transfection levels are 
summarized in Table 5, with transfection levels provided in 
Figure 3. In all pharmacologic studies reported here, no cy-
totoxicity was observed (see Supporting information, Figure 
S2) with the exception of artemisinin (1mM) and nifenazone 
(5mM), where minor toxicity was observed (see Supporting 
information, Figure S2). 
When the ALMS1 gene was activated (phenethicillin) or 
inhibited (quipazine), prior to delivery of lipoplexes, trans-
fection levels were reduced by 7.6-fold or increased by 1.3-
fold, respectively (Figure 3 and Table 5). Similarly, when the 
Table 4. Enriched pathways for genes differentially expressed between GFP+ and GFP– gene expression profiles
Source  Term  Score  Genes
8h
BioCarta  Mesenchymal-epithelial transition factor (MET) pathway  5.53  RAP1A
BioCarta  Integrin pathway  5.43  RAP1A
PPI HUB  HSPA1A  14.27  DNAJB11, PACSIN3, RAP1A
PPI HUB  SMARCA4  6.80  ATF3, RAP1A
CORUM  CLTH (PICALM; phosphatidylinositol binding clathrin assembly protein) complex  8.40  ARMC8
GO  Mitochondrial electron transport, NADH to ubiquinone (GO: 0006120)  8.08  NDUFA10
GO  Regulation of proteolysis (GO: 0030162)  7.74  PACSIN3
GO  Regulation of protein catabolic process (GO: 0042176)  7.54  PACSIN3
16 h
PPI HUB  MAPK9  5.72  TOB1, RAP1A, HSPA6
CORUM  CDC2-PCNA-CCNB1-GADD45A complex  8.06  CCNB1
CORUM  RC complex during G2/M-phase of cell cycle  7.48  CCNB1
CORUM  Cell cycle kinase complex CDC2  7.97  CCNB1
CORUM  RIAM-Rap1-GTP complex  6.47  RAP1A
GO  Spindle (GO: 0005819)  5.03  AURKA
24 h
KEGG  Focal adhesion (HSA04510)  5.57  RAP1A
KEGG  Leukocyte transendothelial migration (HSA04670)  5.36  RAP1A
KEGG  MAPK signaling pathway (HSA04010)  6.21  RAP1A
WIKI  Hepatocyte growth factor receptor signaling (WP313)  5.38  RAP1A
WIKI  IL-3 signaling pathway (WP286)  5.36  RAP1A
WIKI  Interferon type I (WP585)  5.36  RAP1A
BioCarta  MET pathway  5.53  RAP1A
BioCarta  Integrin pathway  5.43  RAP1A
PPI HUB  GABARAPL2  6.07  HSPA6, RAP1A
CORUM  RIAM-Rap1-GTP complex (human)  9.17 RAP1A
GO  Response to protein stimulus (GO: 0051789)  8.85 HSPA6
GO  Response to unfolded protein (GO: 0006986)  8.73  HSPA6
GO  Response to biotic stimulus (GO: 0009607)  7.20  HSPA6
GO  Response to chemical stimulus (GO: 0042221)  5.11  HSPA6
GO  GTPase activity (GO: 0003924) 5.50  RAP1A
Selected enriched terms are listed for differentially expressed transcripts comparing GFP+ microarrays to GFP– microarrays at each indicated time 
point after delivery of pEGFPLuc/LF2000 complexes to HEK 293T cells. The first column indicates the name of pathway database; the second 
column lists the enriched term; the third column lists the enrichment score; and the last column indicates which of the differentially expressed 
genes belong to the enriched term. Downregulated genes are shown in italic, upregulated genes are underlined, and genes greater than five-fold 
differentially expressed are shown in bold. For a description of the source or score, see Materials and methods.
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ITGB1 gene was activated (1,10-phenanthroline) or inhib-
ited (artemisinine), transfection levels were increased by 
1.3-fold or reduced by 5.8-fold, respectively (Figure 3 and 
Table 5).When the FCGR3A gene was activated (ritonavir) 
or inhibited (gentamicin), transfection levels were increased 
by 1.3-fold or decreased by 2.5-fold, respectively (Figure 3 
and Table 5). When the DOCK10 gene was activated (nife-
nazone) or inhibited (8-methoxypsoralen) transfection lev-
els were increased by 1.3-fold or decreased by 1.4-fold, re-
spectively (Figure 3 and Table 5). When the PACSIN3 gene 
was activated (hydralazine) or inhibited (valsartan), trans-
fection levels were decreased by 1.3-fold or increased by 
1.5-fold, respectively (Figure 3 and Table 5). When the ZD-
DHC13 gene was activated (β-acetyl-γ-O-hexadecyl-l-α-
phosphatidylcholine hydrate) or inhibited (nicergoline), 
transfection levels were decreased by 1.1-fold or decreased 
by 1.9-fold, respectively (Figure 3 and Table 5). Taken to-
gether, altering ALMS1, ITGB1, FCGR3A, DOCK10, PACSIN3 
or ZDDHC13 gene activity can affect transfection, showing 
that microarray analysis can identify genes possibly play-
ing a role in transfection. 
The effect of the concentration of the pharmacologic 
agents on transfection used to activate ALMS1 or inhibit 
ITGB1 or FCGR3A was evaluated next (Figure 3) because 
those agents had the largest impact on transfection. For 
phenethecillin (ALMS1 activation), the effect of reduced 
transfection from the pharmacologic treatment became 
less apparent as the concentration of the drug decreased: 
at 10 mM, 100 μM and 1 μM, transfection was reduced 
by 7.60±0.01-, 1.37±0.14- and 1.17±0.02-fold, respectively 
(Figure 4). For artemisinine (ITGB1 inhibition), the effect of 
reduced transfection from the pharmacologic treatment 
also became less apparent as the concentration of the drug 
decreased: at 1 mM, 500 μM, 100 μM and 1 μM, transfec-
tion was reduced by 5.78±0.01-, 2.72±0.11-, 1.72±0.04- and 
1.19±0.04-fold, respectively (Figure 4). For gentamicin (FC-
GR3A inhibition), the effect of reduced transfection from 
the pharmacologic treatment became less apparent as the 
concentration of the drug decreased: at 10mM, 1mM and 
10 μM, transfection was reduced by 2.49±0.04-, 1.18±0.12- 
and 1.15±0.09-fold, respectively (Figure 4). 
Discussion 
Understanding the intracellular molecules and pathways 
that may facilitate DNA transfer provides insight into the 
potential mechanisms required for efficient transfection 
Table 5. Transfection in the presence of pharmacologic agents
   Vehicle Transfection 
Gene  Putative gene function  Pharmacologic agenta   (Control +)    fold changeb
ALMS1  Involved in centriole formation and stability [85] Phenethicillin 10mM ↑ [62]  ddH2O  –76***
 and ciliogenesis [87] Quipazine 1 μM ↓ [62]  ddH2O  1.3*
ITGB1  Ubiquitously expressed adhesion antigen [100], 1, 10-Phen 10 μM ↑ [63]  DMSO  1.3*
 which regulates immune cell chemotaxis [101] Artemisinine 1mM ↓ [64,66]  CHCl3  –58*** 
 and inflammatory response after infection [102].
 Activation mediates proliferation and inhibits
 apoptosis [103]
FCGR3A  FCGR3A transduces signals to cytoplasm, which Ritonavir 10 μM ↑ [64]  DMSO  1.3**
 regulate actin, myosin, membrane fusion and Gentamicin 10mM ↓ [64]  ddH2O  –25
 production of reactive oxygen intermediates during
 phagocytosis of IgG-opsonized particles [93]
DOCK10  Contains a guanine nucleotide exchange factor Nifenazone 10 μM ↑ [62]  DMSO  1.3*
 domain that activates Rho GTPases with growth 8-methoxy 1 μM ↓ [62]  ddH2O  –1.4**
 promoting and anti-apoptotic function; promotes
 actin cytoskeleton reorganization [97] and motility
 via lamellipodia protrusions [98]
PACSIN3  Involved in proteolytic shedding of ectodomain Hydralazine 1 μM ↑ [62]  ddH2O  –13**
 receptors [115] in dynamin-mediated endocytosis [116] Valsartan 100 μM ↓ [64]  DMSO  1.5***
 and tubulin nucleation at the centrosome [117]
ZDDHC13  Palmoylates membrane proteins in Golgi apparatus to B-AGO-PCL 10 μM ↑ [65]  CHCl3  –11
 regulate membrane-to-membrane trafficking [108] or Nicergoline 50 μM ↓ [62]  DMSO  –19
 influence interaction of membrane proteins within lipid
 rafts [109,110], including Ras GTPases such as RAP1 [109]
a. Effect of pharmacologic agent on gene or protein activity as reported in the literature: ↑, activation; ↓, inhibition.
b. Transfection fold change comparing cells treated with pharmacologic agent with cells treated with vehicle only (Control+) (Figure 3).
Transfection levels were measured 24 h after delivery of complexes to HEK 293T cells. The concentration of the pharmacologic agent was selected 
forminimal cytotoxicity and maximal effect (see Supporting information, Figure S2). 1,10-Phen, 1,10-Phenanthroline; 8-methoxy, 8-methoxypsoralen; 
hydralazine, hydralazine hydrochloride; B-AGO-PCL, β-acetyl-γ-O-hexadecyl-l-α-phosphatidylcholine hydrate; ddH2O, double distilled water; 
DMSO, dimethyl sulfoxide; CHCl3, chloroform. Data are reported as the mean (n=3) and significant changes between treated and vehicle-only 
transfection levels are indicated as: * p<0.05 ; ** p<0.01 ; or *** p<0.001.
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[67], offering targets for designing enhanced nonviral gene 
delivery systems. Gene transfer requires molecular medi-
ators to actively transfer the delivered DNA [33] through 
intracellular barriers, into the nucleus [31, 68–76] and for 
transgene expression [77]. Although the routing kinetics of 
the lipoplex have been observed as they occur over time 
Figure 3. Effect of target gene on transfection for HEK 293T cells treated with indicated pharmacologic agent (black bars) or treated 
only with vehicle used to deliver the pharmacologic agent (Control+; open bars) (Table 3) to activate (underlined text) or inhibit 
(plain text) indicated genes. After a 1-h incubation period, lipoplexes were delivered and transfection levels were assayed after 24 h 
(see Materials and methods). Data are reported as the mean±SEM (n=3) and significant changes between treated and vehicle-only 
transfection levels are indicated as: * p<0.05 ; ** p<0.01 ; or *** p<0.001.  
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and enable the development of transfection models [34, 
40, 46, 78, 79], the molecular mediators used by the cell to 
route the DNA complex are poorly understood. In the pres-
ent study, we attempted to fill that gap in knowledge using 
a transcriptomics approach aimed at identifying molecules 
and pathways involved in key cellular events known to in-
fluence transfection at 2, 8, 16 and 24 h after lipoplex de-
livery. Because mRNA metabolism and catabolism can be 
condition- and cell-specific and the mRNA half-life widely 
varies from approximately 10 min to 10 h or more, our ap-
proach may miss the identification of molecules involved in 
short-lived signaling pathways. To address this challenge of 
using microarrays and a few selected time points, we inte-
grated the identified endogenous genes and pathways from 
the present study with other studies that identified short-
lived signaling events into a proposed preliminary model of 
the biology of transfection of HEK 293 T cells by lipoplexes 
(Figure 5). The endogenous genes and pathways are dis-
cussed below in the context of the cellular processes and 
timing of those processes that occur during DNA transfer. 
Treatment of cells with lipoplexes results in a cellular 
downregulation of transcription 
In the present study, gene expression profiles were obtained 
for HEK 293T cells that were treated with lipoplexes for 2 
h compared to untreated cells. Our results show a marked 
downregulation of 44 genes compared to untreated cells 
(Table 1; see also the Supporting information, Table S1) af-
fecting cellular pathways in junction, adhesion, migration 
and inflammation (Figure 5 and Table 2). During this pe-
riod, the treated cells have been reported to internalize li-
poplexes into endosomes and lipoplexes attempt to es-
cape the endosome [22, 34, 40] at the same time as the 
cell is actively coping with the cytotoxic stress induced by 
lipoplexes or foreign DNA [80] (Figure 5). Various strate-
gies have been devised to reduce the cytotoxicity, such as 
maturation time for forming lipoplexes, DNA to liposome 
ratio, size of lipoplexes and serum-free cell culture condi-
tions [80,81]. However, one recent study advocates a molec-
ular method to reduce cytotoxicity, based on knowing what 
gene is involved in the toxicity [7] and we advocate the use 
of a molecular basis to guide the design of improved DNA 
delivery systems with enhanced transfection [44, 45]. Be-
cause all of the genes identified in the present study at the 
2-h time point were highly downregulated, the cellular re-
sponse to exposure of lipoplexes is suggestive of a type of 
cellular shutdown of transcription, presumably to prevent 
further cytotoxic assault [22] and further uptake of foreign 
DNA [80]. We also noted that total RNA was reduced in 
cells treated with lipoplexes compared to untreated samples 
(data not shown), providing further evidence for a transcrip-
tional shutdown. The transcriptional shutdown in response 
to short-term stress is reported to occur in other eukary-
otic systems that act to rapidly destabilize mRNAs and co-
ordinate mRNA turnover within a few minutes to achieve a 
strong activity of stress genes [82]. In the present study, we 
identified those genes that may play a role in processes that 
occur in HEK 293T cells after a 2-h exposure to lipoplexes; 
specifically, ALMS1, ITGB1, DOCK10, FCGR3A and ZDDHC13 
genes (Figure 5 and Table 1), which are discussed below in 
terms of potential hallmarks of the cell shutdown. How-
ever, whether the shutdown event is positive or negative 
for transfection is unclear given the effects of pharmaco-
logic activation of target genes, as discussed below (Table 5 
and Figure 3). The results from our studies demonstrate that 
there are many genes responsible for DNA transfer at dif-
ferent time points and that activating or inhibiting a single 
gene is unlikely to have a prodigious effect on DNA trans-
fer, agreeing with our pharmacologic studies. 
Figure 4. Effect of concentration of pharmacologic on transfection of HEK 293T cells treated with the indicated pharmacologic agent 
(black bars) or treated only with vehicle used to deliver the pharmacologic agent (Control+; open bars) at a range of concentrations. 
After a 1-h incubation period, lipoplexes were delivered and transfection levels were assayed after 24 h (see Materials and meth-
ods). Data are reported as the mean±SEM (n=3) and significant changes between treated and control+ transfection levels are indi-
cated as: * p<0.05 or *** p<0.001.  
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During the first few hours after lipoplex treatment, fi-
lopodia have been reported to play a pivotal role in cel-
lular binding and processing of lipoplexes and polyplexes 
prior to cellular entry via endocytosis [83,84]. Filopodia are 
slender, actin-rich protrusions that extend outward from 
the cell body to sense the extracellular environment. Three 
genes identified in the present study (ALMS1, FCGR3A and 
DOCK10) are implicated in the generation of such podia 
protrusions (Figure 5). ALMS1 is ubiquitously expressed and 
involved in centriole formation and stability [85], the cell cy-
cle [86] and ciliogenesis [87], and contains two nuclear lo-
calization sequences [88], which are all cellular processes 
or molecules that play a role in transfection [37, 39, 83]. 
Because the cellular response at 2 h was to downregulate 
the ALMS1 gene (Table 1), the cell may be acting in defense 
as a result of exposure to foreign DNA by preventing the 
further uptake of lipoplexes via cilia. Hence, we hypothe-
sized that activating ALMS1 with phenethicillin (penicillin 
analog) [62] prior to the delivery of lipoplexes would en-
hance cilia-mediated endocytosis [83, 87] and cell cycle pro-
cesses [39,86] leading to enhanced transfection. Similarly, 
we hypothesized that inhibiting ALSM1 with quipazine (se-
rotonin reuptake inhibitor) [62] prior to lipoplex delivery 
would lead to decreased transfection. By contrast to our 
hypothesis, activating ALMS1 lead to a drastic reduction in 
transfection (7.6-fold) (Table 5) in a dose-dependent man-
ner (Figure 4), at the same time as inhibiting ALMS1 slightly 
increased transfection (1.3-fold) (Table 5). The conflicting re-
sult to our hypothesis highlights: (i) that nonspecific phar-
macologic agents for ALMS1 may not be able to adequately 
test our hypothesis; (ii) that there is a potentially larger role 
of ALMS1 beyond transfection because cilia and basal bod-
ies are involved in many inter- and intracellular processes 
[89,90]; or (iii) that cilia-mediated endocytosis results in an 
intracellular fate of the lipoplex leading to altered degrada-
tion of the lipoplex [91]. In any event, altering ALMS1 levels 
may drastically impact transfection. 
FCGR3A, also implicated in the generation of podia [92] 
that have been shown to facilitate endocytosis of lipoplexes 
[83], was identified as highly downregulated (Table 1) 2 h 
after exposure of HEK 293T cells to lipoplexes. FCGR3A re-
ceptors act to transduce signals to the cytoplasm, which 
Figure 5. Proposed interaction of genes and pathways during pDNA transfer as identified in the present study. Shown is the outline 
of a HEK 293T cell with a partial outline of a daughter cell shown in the upper right. The DNA transfer process is shown within the 
cell, with the initial event of the complex binding to the cell occurring at the far left at time 0 h and subsequent events (large red ar-
rows) occurring over time, from left-to-right. The time points chosen for microarray analysis in the present study are indicated with 
a green arrow at the bottom and correspond to molecular events shown above the arrow within the cell. Genes, enriched pathways 
and molecular intermediates as identified or discussed in the present study at each time point appear in the context of the DNA 
transfer process. Multiple molecular intermediates remain unlisted.   
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regulate actin, myosin, membrane fusion and the produc-
tion of reactive oxygen intermediates during phagocytosis 
of immunoglobulin (Ig)G-opsonized particles [93] by leu-
kocytes [94]. Although HEK 293T is not a leukocyte cell line, 
the FCGR3A receptor can also be found on embryonic epi-
thelial cells [94] and maintain the necessary cellular machin-
ery for endocytosis without exhibiting respiratory burst [95]. 
Activation of the receptor can lead to increased prolifera-
tion [94] and has been reported to enhance viral infection 
[96]. Hence, because of those studies and the impact of po-
dia and endocytosis on transfection [83], we hypothesized 
that activation of FCGR3A with the antiretroviral ritonavir 
[64] would lead to increased endocytosis of lipoplexes and 
therefore increase transfection. Similarly, we hypothesized 
that inhibition of FCGR3A by gentamicin (aminoglycoside 
antibiotic) [64] prior to delivery of lipoplexes would lead to 
reduced transfection. In support of our hypotheses, acti-
vating FCGR3A increased transfection slightly (1.3-fold) (Ta-
ble 5) at the same time as inhibiting FCGR3A drastically re-
duced transfection (2.5-fold) (Table 5) in a dose-dependent 
manner (Figure 4). The distribution of FCGR3A receptor in 
HEK 293T cells should be verified, and the exact mecha-
nisms of FCGR3A in transfection of HEK 293T cells remain 
unclear. However, the results advocate a role of FCGR3A in 
lipoplex-mediated transfection. 
DOCK10, also implicated in the generation of podia that 
have been shown to facilitate endocytosis of lipoplexes 
[83],was identified as being highly downregulated (Table 1) 
2 h after exposure of HEK 293T cells to lipoplexes. DOCK10 
contains a guanine nucleotide exchange factor domain, 
which activates GTPases (such as RAP1A as discussed be-
low) with anti-apoptotic function, promotes actin cytoskel-
eton reorganization and proliferation [97], and enhances 
motility via lamellipodia protrusions [98]. Because DOCK10 
function agrees with observations correlated with transfec-
tion, such as endocytosis of lipoplexes via podia [83], DNA 
repair and activation of protein folding chaperones [44,45], 
cell cycle [39], and cytoskeletal signaling [99], we hypothe-
sized that activation (by nifenazone, a nonsteroidal anti-in-
flammatory agent) [62] or inhibition (8-methoxypsoralen, a 
selective inhibitor of DNA synthesis) [62] of DOCK10 prior 
to delivery of lipoplexes would lead to enhanced or de-
creased transfection, respectively. The results reported in 
the present study support our hypotheses, with activation 
or inhibition of DOCK10 enhancing or reducing transfec-
tion by 1.3- or 1.4-fold, respectively (Table 5). 
Another gene significantly downregulated in cells after 
2 h of exposure to lipoplexes was ITGB1 (Table 1), a ubiqui-
tously expressed adhesion antigen [100], which regulates 
immune cell chemotaxis [101] and the inflammatory re-
sponse after infection [102] (Figure 5). Because the activa-
tion of ITGB1 mediates proliferation and inhibits apopto-
sis [103] and increased cell proliferation is associated with 
increased transfection [39],we hypothesized that activa-
tion (1,10-phenanthroline, uncouples oxidation from phos-
phorylation in metabolic cycle) [63] or inhibition (artemisi-
nine, an antimalarial drug) [64, 66] of ITGB1 would increase 
or decrease transfection, respectively. Indeed, activating 
ITGB1 prior to delivery of lipoplexes resulted in a 1.3-fold 
increased transfection (Table 5), which could be a result of 
its known effect on proliferative capacity of the cells and 
therefore increased transfection [39]. Similarly, inhibiting 
ITGB1 prior to delivery of lipoplexes resulted in drastically 
reduced transfection (5.8-fold) (Table 5) in a concentration-
dependent manner (Figure 4), which could be a result of 
the reduced capacity of ITBG1 to prevent necrosis [102] 
and toxicity induced by the lipoplex [80], which has been 
shown to inhibit transgene expression [104]. The ability of 
ITGB1 to drastically alter transfection provides evidence that 
ITGB1 may be involved in lipoplex-mediated gene deliv-
ery and agrees with one study suggesting that lipoplexes 
electrostatically interact with negative regions of activated 
β-integrins [105] to piggyback internalization along with the 
activated integrins. It was advocated that adhesion recep-
tors, in general, serve as natural cell surface receptors for 
lipoplexes [105] along with other groups showing intercel-
lular cell-adhesion molecule-1, syndecans [106] and integ-
rins [106] to enhance nonviral transfection [107]. Addition-
ally, we advocate a role for integrins in transfection because 
activating RAP1A, involved in integrin-mediated cell adhe-
sion, increases transfection [44,45] (with a role in transfec-
tion as discussed below). 
ZDDHC13 was identified as another gene significantly 
downregulated in cells after 2 h of exposure to lipoplexes 
(Figure 5 and Table 1); ZDDHC13 serves to palmitoylate 
membrane proteins in the Golgi apparatus and regulate 
membrane-to-membrane trafficking [108] or influence 
the interaction of membrane proteins within lipid rafts 
[109,110], including Ras GTPases such as RAP1A [109]. Be-
cause lipid rafts are associated with sites of endocytosis for 
lipoplexes [111, 112], we hypothesized that activation (B-
AGO-PCL, an inflammatory inducer and activator of MAP 
kinase and MAP kinase kinase) [65] or inhibition (nicergo-
line, α-adrenergic receptor antagonist and vasodilator) [62] 
of ZDDHC13 would lead to increased or decreased transfec-
tion, respectively. Activating ZDDHC13 resulted in a slight 
1.1-fold decrease in transfection (Table 5) and did not sup-
port our hypothesis, suggesting that activation of ZDDHC13 
may not be directly involved in transfection or that B-AGO-
PCL is not suitable for testing our hypothesis. However, in-
hibiting ZDDHC13 resulted in a 1.9-fold decrease in trans-
fection (Table 5), which supports our hypothesis suggesting 
that disrupting the ability of the cell to enrich proteins to 
lipid rafts would probably lead to reduced endocytosis of 
lipoplexes and therefore reduced transfection. Increasing 
the concentration of either pharmacologic agent resulted 
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in a cytotoxic effect (data not shown), suggesting that ZD-
DHC13-mediated palmitoylation plays a larger role than 
just membrane trafficking of lipoplexes [113, 114]. The ex-
act mechanism by which transfection is altered by inhibit-
ing ZDDHC13 remains unknown and requires further in-
vestigation, although presumably because of the ability of 
ZDDHC13 to affect lipid rafts, the intracellular fate of the 
lipoplex cargo is also altered, which has been shown to 
drastically influence transfection [76, 91]. In summary, the 
activity of endogenous genes and pathways involved in fi-
lopodia protrusions (ALMS1, FCGR3A and DOCK10), integ-
rin signaling (ITGB1) and membrane trafficking (ZDDHC13) 
may affect transfection early in the DNA transfer process 
(Figure 5). 
Transfected cells overcome cell shutdown and barriers 
to transfection 
As described above, 2 h after lipoplex delivery, all cells ex-
hibited a ‘shutdown,’ as indicated by the highly downregu-
lated nature of all differentially expressed genes (see Sup-
porting information, Table S1). However, although not all 
cells eventually express the transgene, some cells do over-
come the transcriptional shutdown event and express the 
transgene. Several cellular processes are known to occur 
over the course of the next hours (from internalization un-
til transgene expression is detected) (Figure 5), as shown 
by trafficking studies in the literature [21, 31–40]. What re-
mains unknown are the molecules and pathways that par-
ticipate in those processes, thereby preventing the ratio-
nal design of enhanced nonviral gene delivery systems. By 
comparing gene expression profiles for transfected cells 
(GFP+) with untransfected cells (GFP–) over a time course 
of transfection, we were able to identify potential genes 
that may aid in overcoming barriers to transfection. Spe-
cifically, we targeted genes that occur in processes during 
DNA transfer 8, 16 and 24 h after delivery of lipoplexes, as 
described below (Figures 1 and 5). 
Cellular processes that occur 8 h after exposure of lipo-
plexes to cells include endosomal escape [31, 33], followed 
by unpacking of plasmid [31, 32], nuclear localization [31, 
33–36], nuclear entry [34,36,37] and a small amount of GFP 
synthesis [34,38]. By comparing GFP+ and GFP– gene ex-
pression profiles, we found PACSIN3 and RAP1A genes to 
be upregulated at least five-fold, 8 h after exposure to li-
poplexes (Figure 5 and Table 3). PACSIN3 is a gene involved 
in proteolytic shedding of ectodomain receptors [115], act-
ing to reduce dynamin-mediated endocytosis [116] and in-
volved in tubulin nucleation at the centrosome [117]. Given 
the gene product function, we hypothesized that activa-
tion (hydralazine hydrochloride, an inhibitor of mem-
brane-bound enzymes) [62] or inhibition (valsartan, an an-
giotensin-receptor blocker) [64] of PACSIN3 would lead to 
decreased or increased transfection, respectively. Support-
ing our hypothesis, activating PACSIN3 resulted in a 1.3-
fold decrease in transfection presumably as a result of de-
creased endocytosis, which is the primary uptake route of 
lipoplexes into the cell [91]. Similarly, inhibiting PACSIN3 re-
sulted in a 1.5-fold increase in transfection, probably a re-
sult of enhanced endocytosis of lipoplexes or stabilization 
of the microtubule network, which may enhance transport 
of lipoplexes to the cell nucleus [118]. The exact mechanism 
by which PACSIN3 affects nonviral transfection remains un-
clear but, given the processes that occur 8 h after delivery 
of lipoplexes and the putative function of PACSIN3, future 
studies should be conducted to determine the involvement 
of PACSIN3 in endocytosis of lipoplexes, nucleation and 
modification of the microtubule network, and potential en-
hancement in nuclear uptake of pDNA. 
RAP1A was also overexpressed in the GFP+ to GFP– gene 
profile comparison after 8, 16 and 24 h of exposure of lipo-
plexes to the cells (Figure 5 and Table 3). The results sug-
gest that RAP1A plays a role in the cellular processes known 
to occur at those time points: 8 h (endosomal escape [31, 
33], followed by unpacking of plasmid [31, 32], nuclear lo-
calization [31, 33–36], nuclear entry [34, 36, 37] and a small 
amount of GFP synthesis [34,38]); 16 h (nuclear localization 
[34–36], nuclear entry [21, 34, 36, 37] and GFP synthesis 
[34,38]); and 24 h (2 mitosis [36, 39], high nuclear plasmid 
number [34, 36, 37, 40] and the highest production of trans-
gene [34,38,40]). RAP1A is a small G protein (GTPase) that is 
activated by guanine nucleotide exchange factors, growth 
factors, cytokines and many other cell-surface receptors to 
act as a downstream effector promoting proliferation, cell 
survival, vesicular trafficking, cytoskeletal organization, in-
tegrin-mediated cell adhesion, increased proliferation, fo-
cal adhesions and phagocytosis [119, 120]. In our previous 
work, we found RAP1A to be upregulated at the 24-h time 
point in GFP+ cells relative to GFP– cells and that activat-
ing RAP1A prior to lipoplex delivery increased transfection 
two-fold [45], probably affecting cellular processes known 
to affect transfection such as cell cycle [39], cell survival 
[80, 102, 104] and endocytosis [111, 112]. In the present 
study, RAP1A continues to show a potential role in nonvi-
ral gene delivery because RAP1A was overexpressed at 8, 
16 and 24 h when using the nonlinear method for calculat-
ing differential expression [51] (see Materials and methods). 
Two potential RAP1A activators (DOCK10 and ZDDHC13; 
see above) and three effectors (ALMS1, FCGR3A and ITGB1) 
were downregulated 2 h after exposure to lipoplexes. Given 
the 38.62-fold upregulation of RAP1A at the 8-h time point 
(Table 3), it is possible that the cells able to overcome the 
transcriptional shutdown and achieve transfection may be 
those cells that do not exhibit a marked downregulation of 
DOCK10 or ZDDHC13 at the 2-h time point because ac-
tivating those genes, as described above, would lead to 
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enhanced transfection. During the 16- and 24-h time points, 
RAP1A could play a role in vesicular trafficking and cyto-
skeletal organization [119, 120] because activating RAP1A 
acts to acetylate microtubules, which could increase molec-
ular trafficking of lipoplexes to the nucleus, and therefore 
lead to increased transfection [108]. Additionally, GTPase 
signaling transduction (e.g. DOCK10; see above) via cyclic 
adenosine monophosphate and protein kinase A can acti-
vate RAP1A, and protein kinase A has been recently shown 
to modulate intracellular routing of lipoplexes [121]. Taken 
together, a potential relationship among expression levels 
of RAP1Aactivators, RAP1A and RAP1A-effectors with cellu-
lar processes such as focal adhesion, integrin complex, mi-
gration, apoptosis, inflammation and cytoskeletal signaling 
may act together to affect DNA transfer (Figure 5). 
HSPA6 was also overexpressed in the GFP+ to GFP– gene 
profile comparison after 16 and 24 h of exposure of lipo-
plexes to the cells (Figure 5 and Table 3). The results sug-
gest that HSPA6 plays a role in the cellular processes noted 
to occur at those time points [21, 34–40]. HSPA6, heat shock 
70-kDa protein 6 (HSP70B’), is primarily stress inducible and 
acts to maintain cell viability [122,123], although HSPA6 has 
also been shown to facilitate receptor-mediated endocyto-
sis [124], nuclear import of viral particles [125] and podia 
resorption [126]. In our previous work using linear models 
for differential expression determination, we found HSPA6 
to be upregulated at the 24-h time point in GFP+ cells rel-
ative to GFP– cells and that activating HSPA6 prior to lipo-
plex delivery increased transfection by 2.5-fold [45], prob-
ably by altering cellular processes that affect transfection 
such as nuclear import [125], stabilization of transgene pro-
tein folding [122, 123] or podia resorption, which is tied to 
the cell cycle [126]. In the present study, HSPA6 continues 
to show a potential role in nonviral gene delivery because 
HSPA6 was overexpressed at 16h and again at 24 h when 
using the nonlinear method for calculating differential ex-
pression [51] (see Materials and methods). Taken together, 
HSPA6 may also be involved in nonviral transfection by af-
fecting cellular processes such as cell stress/survival, cell 
cycle and the response to unfolded protein (Figure 5). In 
summary, the genes and pathways identified in the present 
study provide a starting foundation for a preliminary model 
of the biology of transfection (Figure 5), as well as for fu-
ture studies to further determine the exact mechanism by 
which transfection is enhanced. 
Conclusions 
Identifying those genes and pathways that aid in overcom-
ing barriers to transfection provides targets for engineer-
ing enhanced delivery systems and enabling their therapeu-
tic use. In the present study, we began such an endeavor 
using microarrays to give a temporal and high throughput 
view of the genes and pathways that occur during DNA 
transfer when using lipoplexes, and extend our endeavor to 
polyplexes (in our complementary work) [48]. In the pres-
ent study, treating cells with lipoplexes showed a transcrip-
tional shutdown of genes involved in cell migration, the in-
flammatory response, adhesion and cell junctions, which 
appear to be important to DNA delivery because of their 
ability to modulate transfection. Possibly more important 
are the genes and pathways utilized by transfected cells 
to overcome cellular barriers to transfection. Those genes 
identified in the present study are involved in metabolism, 
stimuli response, cell adhesion, proliferation and membrane 
transport, and are able to modulate transfection. The genes, 
pathways and pharmacologic agents identified in the pres-
ent study to alter transfection provide a basis to further ex-
plore mechanisms of DNA transfer, prime cells for enhanced 
transfection from existing DNA delivery strategies and en-
gineer novel nonviral systems that can achieve enhanced 
transgene expression.   
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Figure S1. Exploring the interaction among genes and pathways by adding enriched genes and pathways to a network in EGAN to explore and iden-
tify candidate genes for a potential role in transfection for the 2-h time point (A), 8-h time point (B), 16-h time point (C) and 24-h time point (D). 
Temporal endogenous gene express ion prof iles  in response to transfect ion   Suppl. 2
Figure S2. Phase images taken on Leica DMI 3000B (Bannockburn, IL, USA) to assess cell viability and morphology. HEK 293T cells were seeded, al-
lowed to adhere (approximately 18 h); then pharmacologic agent or vehicle control+ was delivered to the media above the cells and after a 1-h in-
cubation, lipoplexes were formed and delivered to the cells. After 24 h, images were taken at ×100 magnification (scale bar is the same for all images 
and as shown is 200 μM), with representative images shown. (A) Phenethicillin 10mM, (B) phenethicillin 100 μM, (C) phenethicillin 1 μM, (D) quipa-
zine 1 μM, (E) 1,10-phenanthroline 10 μM, (F) artemisinine 1mM, (G) artemisinine 500 μM, (H) artemisinine 100 μM, (I) artemisinine 1 μM, (J) ritona-
vir 10 μM, (K) gentamicin 10mM, (L) gentamicin 1mM, (M) gentamicin 10 μM, (N) nifenazone 5mM, (O) 8-methoxypsoralen 10 μM, (P) hydralazine 
hydrochloride 100 μM, (Q) valsartan 100 μM, (R) β-acetyl-γ-O-hexadecyl-l-α-phosphatidylcholine hydrate 10 μM, (S) nicergoline 50 μM, (T) ddH2O 
vehicle control+, (U) CHCL3 vehicle control+, (V) DMSO vehicle control+ and (W) control–. In some cases, when conducting studies using artemis-
inin at a 1mM concentration (F), some locations in the well showed precipitation of the pharmacologic agent and minor toxicity to the cells. Minor 
toxicity was also observed when conducting studies using nifenazone at a 5mM concentration (N).  
Table S1. Genes differentially expressed greater than two-fold at 2, 8, 16 and 24 h after delivery of lipoplexes. 
Time 
Point 
Affy Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression1 
2 h 1558501_at DNM3 dynamin 3 AI631915 0.995 0.478 
 
1555247_a_a
t 
NA NA AF394782 0.990 0.477 
 221765_at UGCG 
UDP-glucose ceramide 
glucosyltransferase 
AI378044 0.993 0.465 
 33148_at ZFR 
zinc finger RNA binding 
protein 
AI459274 0.993 0.346 
 242321_at PTPN14 
protein tyrosine phosphatase, 
non-receptor type 14 
AI628689 0.991 0.346 
 235742_at RHOC ras homolog family member C AI436197 0.997 0.276 
 235318_at FBN1 fibrillin 1 AW955612 0.997 0.111 
 1555890_at BC040701 NA BC040701 0.993 0.110 
 231905_at C20orf96 
chromosome 20 open reading 
frame 96 
AL034548 0.998 0.076 
 233957_at AL117426 NA AL117426 1.000 0.075 
 244303_at AI809906 NA AI809906 0.995 0.073 
 229896_at GTF2I general transcription factor IIi H41907 0.992 0.073 
 231482_at AW274257 NA AW274257 0.998 0.073 
 230574_at LOC100130938 
uncharacterized 
LOC100130938 
AW139393 0.991 0.069 
 1565628_at BM849515 NA BM849515 0.992 0.068 
 1560559_at AL137539 NA AL137539 0.993 0.063 
 214432_at ATP1A3 
ATPase, Na+/K+ transporting, 
alpha 3 polypeptide 
NM_000703 0.995 0.059 
 205666_at FMO1 
flavin containing 
monooxygenase 1 
NM_002021 0.996 0.051 
 220450_at NM_024914 
Homo sapiens hypothetical 
protein FLJ13262 (FLJ13262), 
mRNA 
NM_024914 0.993 0.044 
 220550_at FBXO4 F-box protein 4 NM_018007 0.998 0.042 
 241279_at AV649908 NA AV649908 0.996 0.040 
 1570259_at LIMS1 
LIM and senescent cell antigen-
like domains 1 
BC015843 0.994 0.040 
 1569371_at LRRC59 
leucine rich repeat containing 
59 
BC033695 0.995 0.038 
 214400_at INSL3 insulin-like 3 (Leydig cell) AI991694 0.990 0.036 
 217558_at CYP2C9 
cytochrome P450, family 2, 
subfamily C, polypeptide 9 
BE971373 0.992 0.035 
 237825_x_at R51853 possible contaminated source R51853 0.990 0.032 
 233788_at ALMS1 alstrom syndrome 1 AK021679 0.996 0.029 
 237999_at AW195867 NA AW195867 0.996 0.028 
 
1554240_a_a
t 
ITGAL 
integrin, alpha L (antigen 
CD11A (p180), lymphocyte 
function-associated antigen 1; 
alpha polypeptide) 
BC008777 0.991 0.027 
 240250_at AI912723 NA AI912723 0.991 0.026 
 243036_at CCDC30 
coiled-coil domain containing 
30 
AW364693 0.999 0.026 
 204006_s_at NM_000570 NA NM_000570 0.994 0.026 
 229110_at SLC24A2 
solute carrier family 24 
(sodium/potassium/calcium 
exchanger), member 2 
N50083 0.991 0.024 
 239244_at AI806127 NA AI806127 0.992 0.024 
 244250_at ANXA6 annexin A6 AI917653 0.991 0.024 
 1561042_at ITGB1 
integrin, beta 1 (fibronectin 
receptor, beta polypeptide, 
antigen CD29 includes MDF2, 
MSK12) 
AF086249 0.996 0.023 
 244677_at AA416756 NA AA416756 0.996 0.023 
 220205_at TPTE 
transmembrane phosphatase 
with tensin homology 
NM_013315 0.997 0.022 
 234134_at AF113689 NA AF113689 0.996 0.020 
 219279_at DOCK10 dedicator of cytokinesis 10 NM_017718 0.996 0.020 
 244436_at BF829112 NA BF829112 0.997 0.020 
 
1556171_a_a
t 
BC040304 NA BC040304 0.996 0.018 
 205800_at SLC3A1 
solute carrier family 3 (cystine, 
dibasic and neutral amino acid 
transporters, activator of 
cystine, dibasic and neutral 
amino acid transport), member 
1 
NM_000341 0.991 0.016 
 236491_at BCL2L10 
BCL2-like 10 (apoptosis 
facilitator) 
AI813346 0.990 0.012 
       
8 h 
Affy Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression2 
 
1555340_x_a
t 
RAP1A 
RAP1A, member of RAS 
oncogene family 
AB051846 1.000 38.623 
 222227_at PACSIN3 
protein kinase C and casein 
kinase substrate in neurons 3 
AK000847 1.000 6.641 
 205037_at IFT27 
intraflagellar transport 27 
homolog (Chlamydomonas) 
NM_006860 0.990 3.483 
 217860_at NDUFA10 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 10, 42kDa 
NM_004544 0.993 3.333 
 223054_at DNAJB11 
DnaJ (Hsp40) homolog, 
subfamily B, member 11 
BC001144 0.991 3.025 
 202672_s_at ATF3 activating transcription factor 3 NM_001674 0.999 2.687 
 244528_at ARMC8 armadillo repeat containing 8 AI684748 0.992 0.351 
       
16 h 
Affy Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression2 
 1555339_at RAP1A 
RAP1A, member of RAS 
oncogene family 
AB051846 1.000 17.297 
 213418_at HSPA6 
heat shock 70kDa protein 6 
(HSP70B') 
NM_002155 1.000 7.417 
 1553718_at ZNF548 zinc finger protein 548 NM_152909 0.997 3.074 
 1559291_at LINC00032 
long intergenic non-protein 
coding RNA 32 
AF507950 0.998 2.943 
 202672_s_at ATF3 activating transcription factor 3 NM_001674 0.995 2.856 
 222227_at AK000847 NA AK000847 0.999 2.806 
 214138_at ZNF79 zinc finger protein 79 AA284829 0.999 2.802 
 205021_s_at FOXN3 forkhead box N3 AA860806 0.993 2.403 
 1559995_at SAMD14 
sterile alpha motif domain 
containing 14 
BG911806 0.993 2.233 
 206512_at NM_005083 NA NM_005083 0.997 2.135 
 240789_at W80619 NA W80619 0.991 0.493 
 1555279_at ARMC8 armadillo repeat containing 8 BC007934 0.990 0.481 
 217659_at AA457019 NA AA457019 0.990 0.460 
 204092_s_at AURKA aurora kinase A NM_003600 0.996 0.408 
 228729_at CCNB1 cyclin B1 N90191 0.995 0.408 
 226021_at RDH10 
retinol dehydrogenase 10 (all-
trans) 
AW150720 0.994 0.396 
 215029_at AL117451 NA AL117451 0.994 0.386 
 219031_s_at NIP7 
nuclear import 7 homolog (S. 
cerevisiae) 
NM_016101 0.992 0.380 
 1569142_at TRIM13 tripartite motif containing 13 BC029514 0.992 0.376 
 232861_at PDP2 
pyruvate dehyrogenase 
phosphatase catalytic subunit 2 
AB037769 0.993 0.366 
 
1556410_a_a
t 
KRTAP19-1 keratin associated protein 19-1 AJ457067 0.997 0.355 
 202704_at TOB1 transducer of ERBB2, 1 AA675892 0.994 0.349 
 228273_at PRR11 proline rich 11 BG165011 0.992 0.345 
 204407_at TTF2 
transcription termination factor, 
RNA polymerase II 
AF080255 0.990 0.345 
 206355_at GNAL 
guanine nucleotide binding 
protein (G protein), alpha 
activating activity polypeptide, 
olfactory type 
R20102 0.995 0.342 
 213931_at AI819238 NA AI819238 0.991 0.338 
 
1569181_x_a
t 
BC017896 NA BC017896 0.993 0.329 
       
24 h 
Affy Probe 
ID 
Gene symbol Gene name 
Accession 
number 
Posterior 
Probability 
Differential 
Expression2 
 1555339_at RAP1A 
RAP1A, member of RAS 
oncogene family 
AB051846 1.000 10.28 
 213418_at HSPA6 
heat shock 70kDa protein 6 
(HSP70B') 
NM_002155 1.000 11.35 
1Differential expression represents comparison of microarray gene expression from cells treated with complexes (n = 3) to 
microarray gene expression from cells left untreated (n = 3). 2Differential expression represents comparison of microarray gene 
expression from cells treated and transfection (GFP+; n = 3) to microarray gene expression from cells treated and untransfected 
(GFP-; n = 3. Differential expression greater than or less than 1 represents upregulation or downregulation, respectively. 
 
